ArticleCNS neuroscience & therapeutics2018
Fingolimod-improved axonal and myelin integrity of white matter tracts associated with multiple sclerosis-related functional impairments.
Article in CNS neuroscience & therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Microstructural Alterations of Cerebellar Peduncles in Relapsing Remitting Multiple Sclerosis: a Systematic Review and Meta-Analysis of Diffusion Tensor Imaging Studies.Cerebellum (London, England) · 2024Pooled it
- The association between altitude and cerebral small vessel disease burden in the Tibetan population: a cross-sectional study.Scientific reports · 2025Article
- Immune System and Brain/Intestinal Barrier Functions in Psychiatric Diseases: Is Sphingosine-1-Phosphate at the Helm?International journal of molecular sciences · 2023Review
- Stability of longitudinal DTI metrics in MS with treatment of injectables, fingolimod and dimethyl fumarate.The neuroradiology journal · 2023Article
- High-frequency longitudinal white matter diffusion- and myelin-based MRI database: Reliability and variability.Human brain mapping · 2023Article
- Supplementary Pharmacotherapy for the Behavioral Abnormalities Caused by Stressors in Humans, Focused on Post-Traumatic Stress Disorder (PTSD).Journal of clinical medicine · 2023Article
- Formulating treatment of major psychiatric disorders: algorithm targets the dominantly affected brain cell-types.Discover mental health · 2023Review
- Central nervous system demyelinating diseases: glial cells at the hub of pathology.Frontiers in immunology · 2023Review
- Abnormal oligodendrocyte function in schizophrenia explains the long latent interval in some patients.Translational psychiatry · 2022Review
- Reversing Alzheimer's disease dementia with clemastine, fingolimod, or rolipram, plus anti-amyloid therapy.Alzheimer's & dementia (New York, N. Y.) · 2022Article
- Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year Study.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Article
- Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- Pre-clinical and Clinical Implications of "Inside-Out" vs. "Outside-In" Paradigms in Multiple Sclerosis Etiopathogenesis.Frontiers in cellular neuroscience · 2020Review
- Distinctive functional deficiencies in axonal conduction associated with two forms of cerebral white matter injury.CNS neuroscience & therapeutics · 2019Article
- FTY720 Improves Behavior, Increases Brain Derived Neurotrophic Factor Levels and Reduces α-Synuclein Pathology in Parkinsonian GM2+/- Mice.Neuroscience · 2019Article
- Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy.The Journal of clinical investigation · 2019Article
- Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in.Translational neurodegeneration · 2019Review
- Fingolimod-improved axonal and myelin integrity of white matter tracts associated with multiple sclerosis-related functional impairments.CNS neuroscience & therapeutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsFingolimod hydrochloride is an effective immunomodulatory drug in improving relapsing-remitting multiple sclerosis (RRMS). However, data on the neuroradiologic effects on white matter (WM) have not been demonstrated. In this study, we aimed elucidating the impact of 1-year fingolimod treatment on WM integrity in patients with RRMS.
methodsDiffusion tensor imaging (DTI) was applied to assess axonal and myelin integrity in specific WM tracts of patients with RRMS prior to and 1 year postfingolimod treatment (n = 30). The fractional anisotropy (FA), radial diffusivity (RD), axial diffusivity, and mean diffusivity were analyzed using tract-based spatial statistics on specific regions of interest associated with impaired Expanded Disability Status Scale functional scores before treatment.
resultsIn patients with impaired pyramidal function at baseline (average score 2.3 ± 0.2, n = 25), fingolimod induced a significant increase in FA (P = 0.002) and decrease in RD (P = 0.03) in the corticospinal tract. In patients with impaired cerebellar function at baseline (average score 2.0 ± 0.1, n = 19), significant increases in FA and decreases in RD were observed in the superior (P = 0.02, P = 0.01, respectively) and inferior (P = 0.03, P = 0.05, respectively) cerebellar peduncles.
conclusionThe observed results suggest increased microstructural integrity and decreased demyelination of damaged WM tracts and support the possible direct mechanism of fingolimod action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.